The case of Dr. Anil Kumar, a hepatologist who rose to prominence in India through social media campaigns promoting unproven liver treatments, has drawn sharp criticism from the UK medical establishment. Dr. Kumar, who claims to treat advanced cirrhosis with a combination of herbal remedies and dietary supplements, amassed a large following on platforms such as YouTube and Twitter. However, his methods have been condemned by the General Medical Council (GMC) and the Royal College of Physicians as dangerous and unethical.
The GMC, which regulates doctors in the UK, has issued a statement reiterating that any physician promoting treatments without rigorous scientific evidence risks eroding public trust and endangering patients. Dr. Kumar’s approach, which includes selling expensive supplements through an online store, violates the GMC’s guidelines on financial interests and conflicts of care. The council has warned that similar practices in the UK would lead to immediate investigation and potential removal from the medical register.
This controversy highlights the stark contrast between India’s largely unregulated medical landscape and the UK’s robust governance framework. In India, Dr. Kumar has faced no formal sanctions, despite complaints from medical associations. His popularity underscores a growing distrust in conventional medicine, driven by high costs and limited access for rural populations. In the UK, regulators have moved swiftly to reinforce ethical boundaries. The British Medical Association (BMA) has called for tighter controls on social media marketing by doctors, noting that online platforms can amplify unverified claims to a vulnerable audience.
The case also raises questions about the role of soft power in global health standards. The UK’s insistence on evidence-based practice and institutional oversight serves as a model for other nations. However, as medical tourism and cross-border digital health advice grow, the GMC faces challenges in policing misinformation that originates abroad but reaches British patients. The BMA has urged the government to work with international partners, including India’s Medical Council, to establish common ethical norms.
Dr. Kumar’s defenders argue that he offers hope to patients who have exhausted conventional options. But the GMC’s position remains clear: hope cannot come at the cost of safety. The organisation has published a toolkit for patients to identify unethical practitioners, emphasising that legitimate doctors do not promise cures for incurable diseases.
The British public should take confidence in the stringent rules that govern medicine in this country. While India grapples with the fallout of Dr. Kumar’s rise, the UK’s system ensures that such practices are met with scrutiny and sanction. The integrity of medical governance depends on vigilance, and the GMC’s response sends a firm message: ethics are not negotiable.
